Z24 Bio, Inc.
Z24 Bio provides human-tissue platforms to predict drug toxicity without animal testing. It combines 3D bioprinting, microfluidics, AI, and quantum computing to create scalable tissue models. The company operates as a bioconvergence B2B SaaS/services provider that targets pharmaceutical customers. Its platforms enable earlier toxicity prediction, reduced costs and timelines, and regulatory-aligned testing, with a focus on ethical science and high-throughput capabilities.
Z24 Bio, Inc.
Z24 Bio provides human-tissue platforms to predict drug toxicity without animal testing. It combines 3D bioprinting, microfluidics, AI, and quantum computing to create scalable tissue models. The company operates as a bioconvergence B2B SaaS/services provider that targets pharmaceutical customers. Its platforms enable earlier toxicity prediction, reduced costs and timelines, and regulatory-aligned testing, with a focus on ethical science and high-throughput capabilities.